As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

An­oth­er day, an­oth­er win for En­her­tu.

The an­ti­body-drug con­ju­gate As­traZeneca promised up-to $7 bil­lion to part­ner on has had a quite a few months, be­gin­ning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER